Marc Y Donath

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes
    Claudia Cavelti-Weder
    Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland
    Diabetes Care 35:1654-62. 2012
  2. ncbi request reprint IL-1β activation as a response to metabolic disturbances
    Marc Y Donath
    University Hospital Basel, Switzerland
    Cell Metab 12:427-8. 2010
  3. doi request reprint Type 2 diabetes as an inflammatory disease
    Marc Y Donath
    Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, CH 4031 Basel, Switzerland
    Nat Rev Immunol 11:98-107. 2011
  4. doi request reprint Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
    Marc Y Donath
    Endocrinology, Diabetes, and Metabolism and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
    Cell Metab 17:860-72. 2013
  5. doi request reprint Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes
    Marc Y Donath
    Division of Endocrinology, Diabetes, and Nutrition, and Center for Integrated Human Physiology, University Hospital of Zurich, Zurich, Switzerland
    Physiology (Bethesda) 24:325-31. 2009
  6. doi request reprint Diabetes mellitus Type 2--the new face of an old lady
    Katharina Timper
    Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Switzerland
    Swiss Med Wkly 142:w13635. 2012
  7. doi request reprint Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
    Helga Ellingsgaard
    Clinic for Endocrinology, Diabetes and Metabolism and Department Biomedicine, University Hospital Basel, Basel, Switzerland
    Nat Med 17:1481-9. 2011
  8. pmc How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes
    Marianne Böni-Schnetzler
    Clinic for Endocrinology, Diabetes and Metabolism and Department of Biomedicine, University Hospital of Basel, Basel, Switzerland
    Br J Clin Pharmacol 76:263-8. 2013

Collaborators

Detail Information

Publications8

  1. pmc Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes
    Claudia Cavelti-Weder
    Department of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland
    Diabetes Care 35:1654-62. 2012
    ..Gevokizumab is a novel, human-engineered monoclonal anti-IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type 2 diabetes...
  2. ncbi request reprint IL-1β activation as a response to metabolic disturbances
    Marc Y Donath
    University Hospital Basel, Switzerland
    Cell Metab 12:427-8. 2010
    ..A recent report in Nature Immunology (Masters et al., 2010) identifies amyloid polypeptide as an additional enhancer of IL-1β production...
  3. doi request reprint Type 2 diabetes as an inflammatory disease
    Marc Y Donath
    Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, CH 4031 Basel, Switzerland
    Nat Rev Immunol 11:98-107. 2011
    ....
  4. doi request reprint Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity
    Marc Y Donath
    Endocrinology, Diabetes, and Metabolism and Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland
    Cell Metab 17:860-72. 2013
    ..In this article, we describe the physiology and pathology of the immune system during obesity and diabetes with a focus on islet inflammation, the IL-1β pathway, and clinical translation...
  5. doi request reprint Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes
    Marc Y Donath
    Division of Endocrinology, Diabetes, and Nutrition, and Center for Integrated Human Physiology, University Hospital of Zurich, Zurich, Switzerland
    Physiology (Bethesda) 24:325-31. 2009
    ..We propose that this insulitis contributes to the decrease in beta-cell mass and the impaired insulin secretion observed in patients with Type 2 diabetes...
  6. doi request reprint Diabetes mellitus Type 2--the new face of an old lady
    Katharina Timper
    Clinic of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Switzerland
    Swiss Med Wkly 142:w13635. 2012
    ..This review will highlight recent pathophysiological aspects of type 2 diabetes, actual diagnostic and treatment guidelines and discuss some possible upcoming new therapeutic strategies...
  7. doi request reprint Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
    Helga Ellingsgaard
    Clinic for Endocrinology, Diabetes and Metabolism and Department Biomedicine, University Hospital Basel, Basel, Switzerland
    Nat Med 17:1481-9. 2011
    ..This previously unidentified endocrine loop implicates IL-6 in the regulation of insulin secretion and suggests that drugs modulating this loop may be useful in type 2 diabetes...
  8. pmc How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes
    Marianne Böni-Schnetzler
    Clinic for Endocrinology, Diabetes and Metabolism and Department of Biomedicine, University Hospital of Basel, Basel, Switzerland
    Br J Clin Pharmacol 76:263-8. 2013
    ..Currently, long lasting and specific IL-1β blocking antibodies are being evaluated in clinical trials and this may lead to a novel cytokine-based treatment for type 2 diabetes. ..